PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-933.36%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-933.36%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-1137.19%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-1163.64%
Negative EPS growth while Drug Manufacturers - Specialty & Generic median is 5.99%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-1163.64%
Negative diluted EPS growth while Drug Manufacturers - Specialty & Generic median is 8.34%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-66.98%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-66.98%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
85.06%
OCF/share CAGR of 85.06% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
85.06%
OCF/share CAGR of 85.06% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
85.06%
3Y OCF/share growth of 85.06% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
46.58%
Net income/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 10.73% over a decade. Joel Greenblatt might see a standout compounder of earnings.
46.58%
5Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 9.54%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
46.58%
3Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 7.70%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
-56.80%
Negative 10Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-56.80%
Negative 5Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-56.80%
Negative 3Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 0.52%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.52%
AR shrinking while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman sees potential advantage unless it signals declining demand.
No Data
No Data available this quarter, please select a different quarter.
-9.38%
Assets shrink while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-22.07%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
933.35%
SG&A growth of 933.35% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.